No reliable user-experience data exists — PP-405 is investigational and not available outside clinical trials. From Pelage and Phase 2a published data:

• No felt sensation on application. Topical gel, applied once daily, no acute irritation reported above placebo
• No systemic effect (this is by design — drug is not present in blood)
• No detectable hair regrowth in the first 4 weeks of treatment. The Ki67 stem-cell-activation signal precedes visible regrowth by weeks
• At week 8 (4 weeks post-treatment-end): responders see emerging terminal hairs from previously bald scalp regions. This is the qualitatively novel signal vs minoxidil — not just thicker hair where there was already hair, but new hair from blank scalp
• Side-effect experience reported as minimal: local skin irritation/redness was infrequent and short-lived; no scalp burning, no shedding flare reported as systematic in trials

Reality check: A Phase 2a trial sponsored by the developing company, with subjective scalp photography as part of the readout, has placebo-effect risk and selection-effect risk. The 0% placebo response is striking but the small overall n=78 means the observed 31% responder rate has wide confidence intervals. Phase 3 is the test.

• Tolerance buildup: Unknown. No long-term data. The Phase 2a protocol uses 4-week treatment then 8-week observation, so the question is unanswered.
• Cycling protocol: Not yet established. Phase 3 will likely test continuous vs intermittent dosing.
• Re-treatment: Hypothetical — if Phase 3 succeeds, dosing pattern (continuous? cycle on/off? booster after 6 months?) remains TBD.

For users in this archetype: not actionable now. Track Phase 3 design when announced.

Theoretical synergies (unstudied — Pelage trials are monotherapy)

• Minoxidil (topical or low-dose oral). Mechanism-orthogonal: PP-405 reactivates dormant follicles, minoxidil prolongs anagen and increases shaft caliber. Plausible additive for AGA. No clinical combination data.
• Finasteride / dutasteride. Mechanism-orthogonal: PP-405 reactivates follicles, finasteride blocks DHT-driven miniaturization. Combining could address upstream cause + downstream reactivation in parallel. Already a planned conceptual stack in the AGA community pending PP-405 approval.
• Clascoterone (CB-03-01 / Breezula). Topical AR antagonist — same conceptual lane as topical PP-405. Both are scalp-compartmentalized, both target different mechanisms. Plausible stack for severe AGA.
• Microneedling (cautious). Could enhance PP-405 penetration but may compromise the blood-instability safety profile. Theoretical concern.
• Ketoconazole 2% shampoo. Standard AGA adjunct (anti-inflammatory, mild antiandrogen). No mechanism overlap. Compatible.

Avoid

• Other MPC inhibitors (UK-5099 research-chem, JXL069, dichloroacetate stacks). Mechanism-redundant or mechanism-opposing. Unstudied. UK-5099 and JXL069 are sometimes mislabeled as PP-405 in gray-market sales — running both is a confused experiment.
• Aggressive scalp-barrier disruption (chemical peels, deep microneedling, retinoid escalation) immediately before PP-405. May increase systemic uptake and undermine the safety profile.

Neutral co-administration

• Most systemic biohacking stack components (V4 baseline) — no plausible interaction with a topical MPC inhibitor with no systemic absorption.

• No known CYP enzyme involvement — topical only, no measurable plasma levels.
• No documented drug-drug interactions at the systemic level.
• Theoretical: if scalp barrier is compromised (severe AGA inflammation, dermatitis, microneedling, recent peel) and systemic absorption increases, MPC inhibition could interact with metabolic drugs (metformin, GLP-1 agonists, PDH-axis modulators) — but this is a hypothetical based on mechanism class, not on observed PP-405 pharmacology.

• Minimal directly relevant data. PP-405 has a defined pharmacological target (MPC1/MPC2) but the therapeutic-relevant pharmacogenomic axis would be in target-tissue (HFSC) variants, not systemic metabolism (since the drug doesn't reach circulation).
• Adjacent considerations: SULT1A1 polymorphisms affect minoxidil response; AR/CAG-repeat polymorphisms affect finasteride response. No analogous validated polymorphism affects PP-405 response yet — this would be Phase 3 / post-marketing pharmacogenomic territory.
• For the user's 23andMe data (June 2026): no specific PP-405-relevant variants to look for at this stage.

Verification protocol (when sourcing is real, post-approval):

1. Pelage / authorized distributor only (post-FDA-approval)
2. Standard prescription-Rx verification through licensed pharmacy
3. Until then: clinical trial enrollment is the only legitimate access path

Estimated approval timeline: 2027-2029 if Phase 3 succeeds. Pelage Phase 3 planned to start 2026.

For PP-405 evaluation if sourcing becomes real (post-approval or trial enrollment):

• Baseline (before starting):
  • Trichoscopy or phototrichogram for hair density (hairs/cm²)
  • Terminal vs vellus hair ratio (mechanism-relevant — PP-405 produces terminal not vellus)
  • Hair shaft diameter measurement
  • Photographic global assessment (standardized, same lighting, multiple angles)
  • Hamilton-Norwood (men) or Ludwig (women) staging
  • Optional: baseline scalp biopsy with Ki67 IHC (research setting only)
• During use: Re-photography at 4 weeks, 8 weeks, 12 weeks. Density count at 12 weeks.
• Post-cycle: Re-evaluate at 12 weeks post-final-dose for sustained vs reversed regrowth.
• Long-term: Annual standardized photography for tracking.

For the user's archetype: not currently applicable — track product approval, not biomarkers.